We are excited to announce that our Fund has recently welcomed a new seed-stage company in precision oncology.
StratifAI is a company advancing precision oncology with multimodal artificial intelligence (AI). Their AI model analyses histology images and clinical data to provide meaningful prognostic insights that guide treatment decisions in oncology, particularly in complex oncology cases where traditional methods might fall short.
One of StratifAI’s flagship products is the Breast Cancer Recurrence CDx, an AI-powered test using routinely available histopathology images, that will help clinicians assess the likelihood of cancer recurrence, thereby informing the need for adjuvant chemotherapy. This tool has the potential to be pivotal in personalized treatment planning, allowing for more tailored and effective care for breast cancer patients.
In addition to their diagnostic tools, StratifAI also offers solutions for the biopharmaceutical industry. Their AI tools help in streamlining the drug development process, from early-stage biomarker identification to the optimization of clinical trials, ensuring that new therapies reach the market faster and with greater efficacy.
We have formed strong convictions that delivering precision oncology at scale will require innovative diagnostic and prognostic technologies. Today, many breast cancer patients are subjected to suboptimal and over-aggressive treatments due to the prohibitive costs and inaccessibility of advanced molecular tests necessary for predicting recurrence risks. StratifAI, led by research pioneer Prof. Jakob N. Kather and his team, aims to disrupt this status quo. By using AI to predict breast cancer recurrence risk from routine H&E slides, StratifAI promises to make precision oncology more accessible and affordable, leading to better patient outcomes.
– Nicolas Stalder, Senior Investment Associate at Debiopharm Innovation Fund.
StratifAI is dedicated to increasing access to precision oncology. The participation of Debiopharm in our pre-seed round is a great accelerator for our efforts to involve pharmaceutical stakeholders in our strategic positioning and achieving product-market fit.
– Omar El Nahhas CEO and co-founder of StratifAI.